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ABSTRACT The potent transforming activity of mem-
brane-targeted Raf-1 (Raf-CAAX) suggests that Ras trans-
formation is triggered primarily by a Ras-mediated translo-
cation of Raf-1 to the plasma membrane. However, whereas
constitutively activated mutants of Ras [H-Ras(61L) and
K-Ras4B(12V)] and Raf-1 (ARaf-22W and Raf-CAAX) caused
indistinguishable morphologic and growth (in soft agar and
nude mice) transformation of NIH 3T3 fibroblasts, only
mutant Ras caused morphologic transformation of RIE-1 rat
intestinal cells. Furthermore, only mutant Ras-expressing
RIE-1 cells formed colonies in soft agar and developed rapid
and progressive tumors in nude mice. We also observed that
activated Ras, but not Raf-1, caused transformation of IEC-6
rat intestinal and MCF-1OA human mammary epithelial cells.
Although both Ras- and ARaf-22W-expressing RIE-1 cells
showed elevated Raf-1 and mitogen-activated protein (MAP)
kinase activities, only Ras-transformed cells produced se-
creted factors that promoted RIE-1 transformation. Incuba-
tion of untransformed RIE-1 cells in the presence of condi-
tioned medium from Ras-expressing, but not ARaf-22W-
expressing, cells caused a rapid and stable morphologic
transformation that was indistinguishable from the morphol-
ogy of Ras-transformed RIE-1 cells. Thus, induction of an
autocrine growth mechanism may distinguish the transform-
ing actions of Ras and Raf. In summary, our observations
demonstrate that oncogenic Ras activation of the Raf/MAP
kinase pathway alone is not sufficient for full tumorigenic
transformation of RIE-1 epithelial cells. Thus, Raf-
independent signaling events are essential for oncogenic Ras
transformation of epithelial cells, but not fibroblasts.
Ras proteins are GDP/GTP-regulated switches that function
downstream of receptor tyrosine kinases and upstream of a
cascade of serine/threonine kinases that include the mitogen-
activated protein (MAP) kinases (1-3). Upon activation by
ligand-stimulated receptors, activated Ras complexes with and
promotes the activation of the Raf-1 serine/threonine kinase.
Raf-1 then activates MAP kinase kinases (MEK1 and MEK2),
which in turn activate p42 and p44 MAP kinases also referred
to as extracellular signal regulated kinases (ERKs). The central
role of the Raf-1/MAP kinase pathway in Ras-mediated
transformation of fibroblasts is supported by the observations
that kinase-deficient mutants of Raf-1, MEK, and MAP
kinases are potent inhibitors of Ras signal transduction and
transformation (4-9). Furthermore, since constitutively acti-
vated mutants of Raf-1 or MEK cause tumorigenic transfor-
mation of NIH 3T3 cells (4, 5, 10), activation of the Raf-1/
MAP kinase pathway alone is believed to be sufficient to
mediate Ras transforming activity.
The precise mechanism by which Ras triggers Raf-1 activa-
tion remains to be determined. However, the recent demon-
stration that addition of the Ras COOH-terminal plasma
membrane targeting sequence to Raf-1 converted it to a potent
transforming protein suggested that Ras transformation is
mediated, in large part, by promoting the translocation of
Raf-1 to the plasma membrane (11, 12). Once at the mem-
brane, additional Ras-independent events occur to complete
the activation of Raf-1 kinase activity (13, 14). These obser-
vations, taken together with the comparable transforming
potencies and properties of activated Ras and Raf-1 in rodent
fibroblast transformation assays, support the possibility that
Ras transformation is mediated solely through activation of the
Raf-1/MAP kinase cascade in these cells.
Despite evidence that Raf-1 is a critical downstream target
for Ras, there is increasing evidence that Ras may mediate its
actions by stimulating multiple downstream targets, of which
Raf-1 is only one. First, the recent identification of a mutant
Ras protein that failed to bind Raf-1 yet retained signaling
activities that contribute to Ras transformation suggested that
Raf-1-independent pathways are also important for promoting
full Ras transformation (15). Second, genetic studies of S.
pombe Ras (rasl) function have identified two distinct rasl
effector-mediated activities (16). One involves rasl interaction
with byr2 (a MEK kinase homolog), and the other is triggered
by rasl interaction with scdl (a putative Rho quanine nucle-
otide exchange factor). scdl in turn may regulate the function
of the cdc42sp Rho family protein. Evidence that Ras trans-
formation is also mediated by Rho family proteins in mam-
malian cells includes recent observations that the function of
three Rho family proteins (RhoA, RhoB, and Racl) are
necessary for full Ras transforming activity (17-19). Finally,
the increasing number of candidate Ras effectors provides
additional support for the existence of Raf-independent Ras
signaling pathways (20). Included in this expanding roster of
functionally diverse proteins are the two Ras GTPase activat-
ing proteins (p120 and NF1 GTPase activating proteins), two
guanine nucleotide exchange factors of the Ras-related pro-
teins RalA and RalB (RalGDS and RGL) (21-23) and phos-
phatidylinositol-3-OH kinase (24). Like Raf-1, these proteins
show preferential binding to active Ras-GTP and require an
intact Ras effector domain (residues 32-40) for this interac-
tion. Presently, the contribution of these candidate effectors to
Ras signal transduction and transformation has not been
determined.
Although mutant Ras is most frequently associated with
epithelial cell-derived tumors (25), the majority of Ras signal
transduction and transformation studies have been performed
in rodent fibroblast cells (1-3). Therefore, we were interested
in addressing the possibility that the signaling pathways in-
Abbreviations: MAP, mitogen-activated protein; TGF-a; transform-
ing growth factor type a; ERK, extracellular signal regulated kinase.
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volved in oncogenic Ras transformation of epithelial cells may
differ from those required for transformation ofNIH 3T3 cells.
Unexpectedly, whereas constitutively activated mutants of Ras
and Raf-1 showed comparable transformation of NIH 3T3
cells, only mutant Ras could cause potent tumorigenic trans-
formation of RIE-1 cells. Furthermore, we determined that
constitutively activated Ras, but not Raf-1, caused activation of
a potent autocrine mechanism that contributed significantly to
RIE-1 transformation.
MATERIALS AND METHODS
Molecular Constructs. Mammalian expression vectors con-
taining cDNA sequences for human H-ras, K-ras4B, and
c-raf-1 were generated using the pZIP-NeoSV(x)l retrovirus
vector (neomycin resistant), where expression of the inserted
gene is regulated from the Moloney long terminal repeat
promoter. The pZIP-rasH(61L) and pZIP-rasK(12V) retrovi-
rus expression vector constructs, which encode transforming
mutants of human H-Ras(61L) and K-Ras(12V), respectively,
have been described (26, 27). pZIP-Araf22W and pZIP-raf-
CAAX encode transforming mutants of human c-Raf-1. ARaf-
22W is activated by NH2-terminal truncation (28), whereas
Raf-CAAX is a chimeric protein that contains the COOH-
terminal 18-aa plasma membrane-targeting sequence from
K-Ras4B at the COOH terminus of full-length human Raf-1.
Recent studies have shown that membrane-targeted Raf-1
shows potent transforming activity in NIH 3T3 cells (11, 12).
Cell Culture and Transformation Assays. RIE-1 rat intes-
tinal epithelial cells were maintained in DMEM supplemented
with 5% fetal calf serum. DNA transfections (0.1-10 ,ug of
plasmid DNA per 60-mm dish) were done using 5 ,ul of
Lipofectamine (GIBCO/BRL) for 16-20 hr on cells seeded at
1-5 x 105 per 60-mm dish. NIH 3T3 cells were grown in
DMEM supplemented with 10% calf serum. DNA transfec-
tions (10-25 ng plasmid DNA per 60-mm dish) were done
using calcium phosphate precipitation (29). Transformed foci
were quantitated 21 (RIE-1) or 14-16 (NIH 3T3) days after
transfection. Representative dishes were stained with crystal
violet to visualize transformed foci.
To isolate cell lines stably expressing mutant Ras or Raf-1
proteins, NIH 3T3 and RIE-1 cultures were transfected with
the neo-resistant pZIP expression plasmids and were main-
tained in growth medium supplemented with 400 ,ug/ml G418
(GIBCO/BRL). Multiple G418-resistant colonies were then
pooled together (>50 colonies) and used for growth transfor-
mation assays. To assess colony formation in soft agar, each
transfected cell line was seeded at 103 to 104 cells per 60-mm
dish in growth medium containing 0.3% agar over a base layer
of 0.6%. Tumorigenic growth potential of the transfected
RIE-1 cells was determined by subcutaneous inoculation into
athymic nude mice (1 X 106 cells per site) using procedures
that we have described previously (29).
Raf-1 and MAP Kinase Analyses. Laemmli protein sample
buffer lysates of each transfected cell line were resolved by
SDS/PAGE and transferred onto Immobilon filters for West-
ern blot analyses with the C-12 anti-Raf-1 or K-23 anti-MAP
kinase (p42 and p44) antisera (Santa Cruz Biotechnology).
Detection of secondary antibodywas done by enhanced chemi-
luminescence (Amersham). MAP kinase activation was deter-
mined as described previously in serum-starved cells by West-
ern blot analysis to detect the phosphorylated, active and
nonphosphorylated, inactive forms of p42MAPK/ERK2 and
p44MAPK/ERK1 (7). The MAP kinase immunocomplex assay
was carried out by incubating the immunoprecipitated MAP
kinase with myelin basic protein in a kinase assay for 30 min
at room temperature. The reactions were then stopped using
2x SDS sample buffer. The proteins were then separated on
an SDS/15% polyacrylamide gel and visualized by autoradiog-
raphy (30). Raf-1 kinase activity was determined by immuno-
precipitation of Raf-1 using the C12 anti-Raf-1 antiserum from
detergent lysates [modified RIPA buffer: 150 mM NaCl/1%
(vol/vol) Nonidet P-40/50% (wt/vol) sodium deoxycholate/5
mM EDTA/50 mM Hepes, pH 7.5/1 mM Na3VO4/50 mM
NaF/1 ,M okadaic acid/i mM phenylmnethylsulfonyl fluo-
ride/5 mM benzamidine/0.1% (vol/vol) aprotinin] derived
from each cell line. The immune-complexed Raf-1 was then
combined with 26 ,ul of kinase mix, which consisted of 4 ,ul of
lOX universal kinase buffer (0.1 M Tris HCl, pH 7.5/0.1 M
MgCl2/10 mM DTT), 1 mM ATP, and 5 ,uCi of 32P-ATP, and
0.5 ,ug of recombinant human wild-type MEK1 for 15 min, and
then 2.0 ,tg of recombinant kinase-deficient MAP kinase was
added for an additional 15 min. The reaction was terminated
by the addition of Laemmli protein sample buffer.
Conditioned Media Assay. After 2 days, 5 ml of medium was
collected from confluent cultures of RIE-1 cells stably trans-
fected with either the empty pZIP-NeoSV(x)l vector or pZIP
constructs encoding mutant Ras or ARaf-22W proteins. After
filtration through a 0.22 ,uM filter, the different conditioned
media, or fresh growth medium supplemented with 20 ng/ml
transforming growth factor type a (TGF-a), were added onto
subconfluent cultures (103 to 104 cells per 60-mm dish) of
untransformed RIE-1 cells. Cells were monitored for 24-48 hr
for morphological changes, and photographs were taken after
18 hr.
RESULTS
RIE-1 is an established rat intestinal cell line that displays
properties of normal epithelial cells (31, 32). We first deter-
A.
Vector H-Ras(61 L)
B Vector H-Ras(61 L)
ARaf-22W Raf-CAAX
FIG. 1. Activated H-Ras(61L), but not Raf-1, causes focus-forming
activity in RIE-1 cells. (A) Appearance of transformed foci in Ras-
transfected RIE-1 cells was detected 21 days after transfection. (B)
Oncogenic H-Ras(61L), but not ARaf-22W or Raf-CAAX, caused the
appearance of transformed foci in RIE-1 cells. Representative dishes
were stained with crystal violet to visualize transformed foci.
Biochemistry: Oldham et al.
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mined the sensitivity of RIE-1 cells to transformation by
constitutively activated mutants of Ras and Raf-1. For these
analyses, we used expression vectors that encoded oncogenic
H-Ras(61L) or K-Ras4B(12V) and two different activated
mutants of Raf-1 (ARaf-22W and Raf-CAAX). The Ras and
Raf expression vectors were previously shown to cause com-
parable focus-forming activities in NIH 3T3 assays (3-4 x 103
foci/,ug or 1-2 x 103 foci/gg of transfected plasmid DNA,
respectively) (26, 28). Surprisingly, whereas oncogenic mu-
tants of Ras readily induced transformed foci in RIE-1 cultures
that were transfected with as little as 100 ng of plasmid DNA
('50 foci/,tg ofDNA) (Fig. 1A), no focus-forming activity was
observed in cultures transfected with up to 10 ,tg of plasmid
DNA encoding the two Raf-1 mutants (Fig. 1B) (11, 12, 28).
Thus, activated Raf-1, but not Ras, showed differential abilities
to cause focus-formation in RIE-1 and NIH 3T3 cells.
We next evaluated the biological properties of RIE-1 cells
stably transfected with constructs encoding the different trans-
forming mutants of Ras and Raf-1. Whereas untransformed
RIE-1 cells displayed a very flat, well-adherent and nonre-
fractile appearance, Ras-transformed RIE-1 cells were very
refractile and poorly adherent (Fig. 24). In contrast, the
morphology of ARaf-22W- or Raf-CAAX-transfected cells
was indistinguishable from the control RIE-1 cells, which were





pression vector. Furthermore, Ras-transfected, but not Raf-
transfected, cells showed the ability to form colonies in soft
agar (Fig. 2B). Finally, we determined whether mutant Ras or
Raf expression caused tumorigenic transformation of RIE-1
cells. Inoculation of Ras-transformed cells into athymic nude
mice caused rapidly growing tumors that were greater than 1
cm in diameter within 6 days. In contrast, ARaf-22W-
transfected cells were negative for tumor formation until day
27, at which time slow-growing tumors became detectable.
Data from a representative nude mouse assay are summarized
in Table 1. These results contrast with the analyses ofNIH 3T3
cells, where both Raf- and Ras-transformed NIH 3T3 cells are
highly tumorigenic in nude mice.
The failure of both Raf-1 expression constructs to cause
transformation of RIE-1 cells may simply be due to the
absence of Raf-1 protein expression from these exogenously
introduced raf expression constructs. To address this possibil-
ity, we performed Western blot analysis using the C-12 anti-
Raf-1 antiserum on cell lysates from stably transfected RIE-1
cells. Whereas RIE-1 cells stably transfected with the pZIP-
Araf22W construct showed high levels of the NH2-terminal
truncated ARaf-22W (-37 kDa) protein (Fig. 3A), we could
not readily detect Raf-CAAX expression in the stably trans-
fected RIE-1 cells. This may be due to the apparent growth
inhibitory activity that we have observed with Raf-CAAX in
H-Raa(61 L) Rat-22W
K-Ras(1 2V)
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FIG. 2. Activated Raf-1 fails to cause morphologic or anchorage-independent growth of RIE-1 cells. Stably transfected RIE-1 cells expressing
oncogenic H-Ras(61L) or K-Ras(12V), but not ARaf-22W or Raf-CAAX, are morphologically transformed (A) and can form colonies in soft agar
(B). In contrast, both ARaf-22W and H-Ras(61L) caused morphologic transformation and growth in soft agar (data not shown) of NIH 3T3 cells.
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Table 1. Tumorigenicity analysis of Ras- and Raf-expressing
RIE-1 cells
Day of Mean volume,
Plasmid* appearancet Day of death mm3
pZIP-rasK(12V) 6 (4/4) 19 1436.3
pZIP-raf22W 27 (4/4) 36 510.5
pZIP-
NeoSV(x)1 (0/4) 42 N/A
N/A, not applicable.
*Pooled populations of G418-resistant colonies transfected with the
indicated plasmid DNA.
tNumber of animals positive for tumor formation/number of animals
injected.
RIE-1 (and NIH 3T3) cells and suggests that the biological
properties of these two Raf-1 mutants are not identical.
Whereas RIE-1 cultures transfected with either empty vector,
pZIP-ras, or pZIP-Araf22W, followed by selection in G418-
containing growth medium, resulted in the efficient appear-
ance of drug-resistant colonies, a considerably reduced fre-
quency of colonies was observed with cultures transfected with
pZIP-raf-CAAX (data not shown). However, the high levels of
ARaf-22W expression indicate that the failure of this mutant
to cause transformation is not due to lack of expression.
Neither NH2-terminal truncation (ARaf-22W) nor the ad-
dition of a plasma membrane targeting sequence (Raf-CAAX)
alone is sufficient to activate Raf-1 kinase activity (13, 14).
Thus, it is possible that other events required to trigger the
activation of ARaf-22W or Raf-CAAX transforming activity
may not occur in RIE-1 cells (14). To address this possibility,
we measured Raf-1 kinase activity in Ras- and Raf-expressing
cells using an in vitro MEK-dependent MAP kinase phosphor-
ylation assay. Whereas Raf-1 kinase activity was low in control,
vector-transfected cells, Raf-1 kinase activity was greatly ele-
vated in both oncogenic Ras- and ARaf-22W-expressing cells
(Fig. 3B). Additionally, we detected low levels of constitutively
activated MAP kinase activity in both Ras- and Raf-expressing
cells by the appearance of the slower migrating, phosphory-
lated and activated forms of p42 and p44 (Fig. 3C) and by using
a MAP kinase immune-complex kinase assay (data not
shown). Thus, constitutive Raf and MAP kinase activity alone
is not sufficient for transformation of RIE-1 cells, and Ras may
trigger the stimulation of Raf/MAP kinase-independent
events to promote tumorigenic transformation of RIE-1 cells.
Since up-regulation of TGF-a has been observed in Ras-
transformed IEC-18 rat intestinal epithelial cells (33), we
evaluated the possibility that the induction of an autocrine
growth mechanism may distinguish the transforming activities
of Ras and Raf-1 in RIE-1 cells. Whereas conditioned medium
from vector-transfected cells showed no activity when added
on to untransformed RIE-1 cells, conditioned medium from




transformation that was indistinguishable from the highly
refractile and rounded morphology of Ras-transformed RIE-1
cells (Fig. 4). In contrast, conditioned medium from ARaf-
22W-expressing cells did not cause morphologic transforma-
tion of RIE-1 cells. Finally, since we have observed that TGF-a
expression is enhanced 50-fold in oncogenic Ras-expressing,
but not ARaf-22W-expressing, RIE-1 cells (unpublished data),
we determined whether TGF-a alone could cause the same
changes as conditioned medium from Ras-transformed cells.
Although growth of untransformed cells in the presence of 20
ng/ml TGF-a resulted in morphologic transformation, the
effect was only transient (<24 hr) and distinct from the
persistent changes that were seen with the conditioned me-
dium from Ras-transformed cells. Therefore, although we
have observed that TGF-a alone is sufficient to promote the
growth of untransformed RIE-1 cells in soft agar (data not
shown), TGF-a is not likely to be the only component present
in the conditioned medium that contributes to RIE-1 trans-
formation. We conclude that constitutive activation of Ras, but
not Raf-1, causes induction of an autocrine mechanism that
may contribute significantly to transformation of RIE-1 cells.
DISCUSSION
Since constitutive activation of either Ras or Raf-1 causes full
tumorigenic transformation ofNIH 3T3 fibroblasts, it has been
suggested that oncogenic Ras causes transformation solely by
promoting activation of the Raf/MAP kinase cascade (11, 12).
However, in this study we observed that activated Raf-1,
despite triggering constitutively elevated Raf-1 and MAP
kinase activity, failed to cause morphologic and growth trans-
formation of RIE-1 epithelial cells in vitro. Thus, oncogenic
Ras-mediated up-regulation of the Raf/MAP cascade alone is
not sufficient to cause potent transformation of RIE-1 epi-
thelial cells. Since we have also observed that activated Ras,
but not Raf-1, causes transformation of the IEC-6 rat intestinal
and the MCF-1OA human breast epithelial cell lines (data not
shown), we suggest that oncogenic Ras requires activation of
additional, Raf-independent pathways to cause potent mor-
phologic and growth transformation of epithelial cells.
Although the Raf-expressing RIE-1 cells lacked the rapid
tumorigenic growth properties seen with Ras-transformed
RIE-1 cells, a delayed onset of tumor formation that was not
seen for the vector-transfected RIE-1 cells was observed. One
possible explanation for the latent tumorigenic capability of
Raf-expressing cells may be that a subpopulation of cells with
greatly enhanced Raf-1 expression was responsible for tumor
formation. However, these tumor-derived cells did not show
increased Raf-1 protein or kinase expression when compared
with the cells that were injected (data not shown). Instead, it
is likely that secondary genetic events that complement acti-
vated Raf-1 to promote full tumorigenic transformation have











FIG. 3. Ras- and Raf-expressing cells possess constitutively activated Raf-1 and MAP kinases. (A) ARaf-22W protein expression in stably
transfected cells. Lysates from equivalent numbers of each transfected cell line were resolved by SDS/PAGE and transferred onto Immobilon filters
for Western blot analysis with the C12 anti-Raf-1 antiserum. (B) In vitro Raf-1 kinase assays were done on cell lysates from equivalent numbers
of cells. (C) The reduced electrophoretic mobility of the phosphorylated, active forms of p42MAPK/ERK2 and p44MAPK/ERK1 are indicated by
an asterisk.
Biochemistry: Oldham et al.




* . % .. .. ~~~~~~~~~~.........





FIG. 4. Conditioned medium from Ras-expressing, but not Raf-
expressing, RIE-1 cells causes morphologic transformation of RIE-1
cells. Media collected from confluent cultures of RIE-1 cells stably
transfected with either the empty pZIP-NeoSV(x)1 vector or the pZIP
constructs encoding transforming Ras or Raf-1 proteins, or fresh
growth medium supplemented with 20 ng/ml TGF-a were added onto
subconfluent cultures of parental RIE-1 cells and the cultures were
photographed after 18 hr.
derived Raf-expressing cells caused rapid tumor formation
when re-inoculated into nude mice.
Our observation that oncogenic Ras activation of the Raf/
MAP kinase pathway alone is not sufficient to cause trans-
formation of RIE-1 cells raises several questions. First, al-
though it is clearly insufficient, is Raf/MAP kinase activation
necessary for Ras transformation of RIE-1 cells? Our obser-
vation that a mutant of oncogenic Ras [Ras(12V, 37G)], which
shows impaired transforming activity in NIH 3T3 cells primar-
ily as a consequence of a defective interaction with Raf-1 (15),
also showed impaired transforming activity in RIE-1 cells
suggests that Raf-1 activation both contributes to, and is
necessary for, Ras transformation of RIE-1 cells. Second, what
are the other Ras-mediated, Raf-independent pathways re-
quired for RIE-1 transformation? Possibilities include signal-
ing pathways that involve members of the Rho family of
Ras-related proteins (17-19) or that involve RalGDS regula-
tion of the Ras-related protein Ral (21-23). Therefore, it
would be interesting to determine if coexpression of consti-
tutively activated mutants of Rho or Ral promotes Raf-
mediated transformation of RIE-1 cells. Finally, what aspect of
oncogenic Ras transformation is mediated by an autocrine
mechanism? Our observation that exogenous TGF-a alone
could cause morphologic transformation, as well as promote
growth in soft agar, suggests that TGF-a is a major component
of the activity detected in the medium from Ras-transformed
RIE-1 cells. However, whereas treatment of cells with condi-
tioned medium caused a persistent morphologic transforma-
tion, TGF-a alone caused a transient morphologic transfor-
mation. Therefore, we suspect that autocrine factors secreted
by Ras-transformed cells include additional factors that pro-
mote Ras transformation. Similarly, it has been reported that
TGF-a contributes to, but alone is not sufficient to cause,
transformation of IEC-18 rat intestinal epithelial cells (33).
In summary, we have shown that oncogenic Ras activation
of the Raf/MAP kinase pathway alone is insufficient to cause
transformation of RIE-1 cells. Since the majority of tumors
that harbor mutant Ras are derived from epithelial cells (25),
the identification of the Raf-independent signaling pathways
that contribute to oncogenic Ras transforming activity in
human carcinomas will clearly be important. The components
that mediate these signaling pathways may represent important
new targets for the development of anti-Ras drugs and cancer
treatment.
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